HER2- Breast Cancer Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

HER2- Breast Cancer Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Summary

This reports provides a data-driven overview of the current and future competitive landscape in HER2- Breast Cancer therapeutics.

Synopsis

  • In 2022, there will be more than one million incidence cases of HER2- BC across 16 pharmaceutical markets.
  • There are several marketed innovator drugs for the treatment of HER2- BC, mostly kinase inhibitors.
  • A total of seven pipeline drugs for HER2- BC are in pre-registration phase and 42 drugs are in Phase III.
  • Commercial sponsors dominate clinical trial development in HER2- BC, with the US emerging as the key country for conducting Phase III trials in HER2- BC.
  • Partnership was the most common type of deal in North America and Europe, while licensing agreements were the most prominent deal type in South America and Africa.
  • Within the next 24 months, several new product launches within HER2- Breast Cancer space are expected.
Scope

GlobalData’s HER2- Breast Cancer Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -
  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Pricing and Reimbursement Assessment
  • Retail or Manufacturer Price of Products
  • Time to Pricing and Time to Reimbursement
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the HER2- Breast Cancer market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HER2- Breast Cancer market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.


  • Key Findings
  • Disease Overview
  • Epidemiology Overview
    • Epidemiology Overview: Incident Cases of HER2- BC in 2022 and 2027
  • Treatment Overview
    • Treatment Guidelines
  • Marketed Drugs Assessment
    • Marketed Drugs - Leading Marketed Drugs in HER2- BC
    • Marketed Drugs - Overview by Mechanism of Action
    • Marketed Drugs - Overview by Route of Administration
    • Marketed Drugs - Overview by Molecule Type
    • Marketed Drug Profile: Merck & Co/MSD's Keytruda
    • Marketed Drug Profile: AstraZeneca's Lynparza
    • Marketed Drug Profile: Pfizer's Ibrance
    • Marketed Drug Profile: AstraZeneca's Faslodex
    • Marketed Drug Profile: Novartis's Kisqali/Kryxana
    • Marketed Drug Profile: Pfizer's Talzenna
    • Marketed Drug Profile: Novartis's Afinitor
    • Marketed Drug Profile: Eli Lilly's Verzenio/Verzenios
    • Marketed Drug Profile: Novartis's Piqray
    • Marketed Drug Profile: Gilead's Trodelvy
  • Pricing and Reimbursement Assessment
    • Marketed Drugs - manufacturer price (in $/mg) for oral formulations for HER2-BC
    • Marketed Drugs - manufacturer price (in $/mg) for non-oral formulations for HER2-BC
    • Marketed Drugs - manufacturer price ($/mg)
    • Marketed Drugs - time to pricing and reimbursement for Olaparib
      • Table Olaparib - time to pricing and reimbursement (in days)
    • Marketed Drugs - time to pricing and reimbursement for Palbociclib
      • Table Palbociclib - time to pricing and reimbursement (in days)
    • Marketed Drugs - time to pricing and reimbursement for Ribociclib
      • Table Ribociclib - time to pricing and reimbursement (in days)
    • Marketed Drugs - time to pricing and reimbursement for Abemaciclib
      • Table Abemaciclib - time to pricing and reimbursement (in days)
    • Marketed Drugs - time to pricing and reimbursement for Alpelisib
      • Table Alpelisib - time to pricing and reimbursement (in days)
    • Marketed Drugs - time to pricing and reimbursement for Talazoparib
      • Table Talazoparib - time to pricing and reimbursement (in days)
    • Marketed Drugs - time to pricing and reimbursement for Pembrolizumab
      • Table Pembrolizumab - Time to pricing and reimbursement (in days)
    • Marketed Drugs - time to pricing and reimbursement for Fulvestrant
      • Table Fulvestrant - Time to pricing and reimbursement (in days)
    • Marketed Drugs - time to pricing and reimbursement for Sacituzumab
      • Table Sacituzumab - Time to pricing and reimbursement (in days)
  • Pipeline Drugs Assessment
    • Pipeline Drugs Overview - Pre-registration and Phase III Pipeline Drugs in HER2- BC
    • Pipeline Drugs - Overview by Development Stage
    • Pipeline Drugs - Overview by Mechanism of Action
    • Pipeline Drugs - Overview by Route of Administration
    • Pipeline Drugs - Overview by Molecule Type
    • Pipeline Drugs - Drug-Specific Phase Transition Success Rate and Likelihood of Approval in HER2- BC
      • Table HER2- BC
      • Table TNBC
    • Pipeline Drugs - Phase Transition Success Rates and Likelihood of Approval in Oncology and in HER2- BC
  • Clinical Trials Assessment
    • Clinical Trials in HER2- BC - Historical Overview
    • Clinical Trials in HER2- BC - Overview by Phase
    • Clinical Trials in HER2- BC - Overview by Status
    • Clinical Trials in HER2- BC - Overview by Phase for Ongoing and Planned Trial
    • Clinical Trials in HER2- BC - Trials with a Virtual Component
    • Clinical Trials in HER2- BC - Geographic Overview
    • Clinical Trials in HER2- BC - Single-Country and Multinational Trials by Region
    • Clinical Trials in HER2- BC - Top 20 Sponsors with Breakdown by Phase
    • Clinical Trials in HER2- BC - Top 20 Sponsors with Breakdown by Status
    • Clinical Trials in HER2- BC - Overview by Endpoint Status
    • Clinical Trials in HER2- BC - Overview by Race and Ethnicity
    • Clinical Trials in HER2- BC - Enrollment Data
      • Table Enrollment data for Phase II trials in HER2- BC
      • Table Enrollment data for Phase III trials in HER2- BC
    • Clinical Trials in HER2- BC - Overview of Sites by Geography
    • Clinical Trials in HER2- BC - Top 20 Countries for Trial Sites
    • Clinical Trials in HER2- BC - Top 20 Sites Globally
    • Clinical Trials - Feasibility Analysis: Geography Overview
      • Table HER2- BC
      • Table TNBC
    • Clinical Trials - Feasibility Analysis: Benchmark Models for HER2- BC
  • Deals Landscape
    • Deals Landscape - Mergers, Acquisitions, and Strategic Alliances in HER2- BC by Region
    • Deals Landscape - Recent Mergers, Acquisitions, and Strategic Alliances in HER2- BC
  • Commercial Assessment
    • Commercial Assessment - Key Market Players in HER2- BC
  • Future Market Catalysts
    • Future Market Catalysts - Upcoming Market Catalysts in HER2- BC
  • Appendix
    • Methodology
    • Methodology - Sales Forecasts
    • Methodology - Pricing and Reimbursement
    • Methodology - Phase Transition Success Rate and Likelihood of Approval Analysis
    • About the Authors
  • Contact Us
    • Contact Us - A Global Network of Offices

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings